V Buettiker1, M I Hug, R Burger, O Baenziger. 1. Department of Neonatology and Intensive Care, University Children's Hospital, Zurich, Switzerland. vera.buettiker@kispi.unizh.ch
Abstract
BACKGROUND: The standard treatment of chylothorax in pediatric intensive care today includes conservative therapy with fat-free nutrition, total parenteral nutrition and, if this is not successful, operative treatment (pleurodesis, ligation of the duct, pleuroperitoneal shunt). PATIENTS: We describe four patients who were not in a suitable condition for operative treatment and who were treated with continuous infusion of somatostatin. RESULTS: In three patients, chylothorax ceased with the continuous somatostatin infusion without side effects. One patient was treated without success. CONCLUSIONS: Somatostatin is a therapeutic option for treatment of chylothorax and could reduce surgical intervention and hospitalization time, as well as allow earlier enteral feeding.
BACKGROUND: The standard treatment of chylothorax in pediatric intensive care today includes conservative therapy with fat-free nutrition, total parenteral nutrition and, if this is not successful, operative treatment (pleurodesis, ligation of the duct, pleuroperitoneal shunt). PATIENTS: We describe four patients who were not in a suitable condition for operative treatment and who were treated with continuous infusion of somatostatin. RESULTS: In three patients, chylothorax ceased with the continuous somatostatin infusion without side effects. One patient was treated without success. CONCLUSIONS:Somatostatin is a therapeutic option for treatment of chylothorax and could reduce surgical intervention and hospitalization time, as well as allow earlier enteral feeding.
Authors: Rod E Urizar; Kenneth Kolnacki; Robert Kaslovsky; Paul Comber; Gary Siskin; Eric Dolen Journal: Pediatr Nephrol Date: 2003-03-18 Impact factor: 3.714
Authors: Charles C Roehr; Andreas Jung; Hans Proquitté; Oliver Blankenstein; Hannes Hammer; Kokila Lakhoo; Roland R Wauer Journal: Intensive Care Med Date: 2006-03-11 Impact factor: 17.440